PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a firm specializing in non-opioid pain management solutions, has reached a settlement with Takeda Pharmaceuticals U.S.A., Inc. and its parent company Takeda Pharmaceuticals Company LTD. This agreement resolves a patent infringement lawsuit related to Scilex's gout medication, Gloperba.
The dispute originated in November 2023 when Takeda filed a lawsuit against Scilex after the latter sought to expand the label for Gloperba, its FDA-approved liquid colchicine product for preventing gout flares.
As part of the settlement, Scilex has obtained a non-exclusive license to certain Takeda patents. While the specific terms remain confidential, the settlement is pending approval by the district court and regulatory authorities, including the Federal Trade Commission and the U.S. Department of Justice, as required for Paragraph IV patent case settlements.
Scilex's portfolio includes ZTlido, a lidocaine topical product for post-shingles nerve pain, and ELYXYB, an oral solution for acute migraine treatment. The company also has several product candidates in development, such as SP-102, a corticosteroid gel for sciatica, and SP-104, a low-dose naltrexone for fibromyalgia, with clinical trials expected to commence in 2024.
The settlement with Takeda is a significant step for Scilex as it prepares to launch Gloperba in the first half of 2024. This move could potentially enhance the company's position in the market for gout treatment, which affects a substantial patient population.
This report is based on a press release statement from Scilex Holding Company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.